AKT1 and familial dilated cardiomyopathy: Despite the limited evidence highlighting the significance of targeting GLP1R as a potential treatment for DCM, to our knowledge, no study has yet elucidated the interplay between GLP1R and the ILK/PI3K/AKT/PTEN signaling pathways in the context of DCM.